Source non-cytotoxic pharmaceutical waste from manufacturing and healthcare. Solvent recovery and co-processing routes. Connect with licensed receivers via SymbioFlows.
~500k t/yr
EU annual generation
Cost €150–600/t depending on classification
Typical market range
18 01 09
Primary EWC classification
| # | Route | Buyer Type | Price Range |
|---|---|---|---|
| 1 | Co-processing in cement kiln | Cement producers (licensed) | Cost €150–300/t |
| API residues with CV >15 MJ/kg accepted; inorganic content enters clinker | |||
| 2 | High-temperature incineration | Licensed hazardous waste incinerators | Cost €250–600/t |
| Required for cytotoxic, hormone-active, or unclassified API waste | |||
| 3 | Solvent recovery (production solvents) | Solvent re-distillers | Credit €200–600/t for pure streams |
| Applicable to production solvent streams — not end-of-life medicines | |||
Primary code: 18 01 09
How pharma waste fits into a wider valorisation strategy.
Pharma Waste
With a lab analysis, the engine checks the stream against each receiving route's published limits and returns what is supported, what is refused, and why. Without one yet, we tell you which routes it can evaluate and what analysis that needs.
See what the output looks like: a worked dossier.